Pharmacogenomic Testing for Antidepressants Could Save Time,

A model showed that pharmacogenomic testing of patients with newly diagnosed major depressive disorder could save the health system $956 million CAD over 20 years.

Related Keywords

United Kingdom , Calgary , Alberta , Canada , Canadian , British , Canadians , Shahzad Ghanbarian , Canadian Medical Association Journal , World Health Organization , Clinical Pharmacogenetics Implementation Consortium , University Of Calgary , British Columbia , Clinical Epidemiology , Medscape Medical , Canadian Medical Association , Depression , Genomics , Genomic Medicine , Edicine Genomic , Cost Effectiveness Research , Cost Benefit Analysis , Pharmacogenomics , Personalized Medicine , Major Depression , Major Depressive Disorder , Nipolar Depression , Antidepressant , Antidepressant Drug , Rug Antidepressant , , Refractory , Patient Safety , Adverse Effects , Side Effects , Genetics , Health Care Economics , Conomics ,